Soliton, Inc. SOLY
Day range unavailable
52-week range unavailable
Discussion (139)
Sign in to join the discussion
$SOLY lets go!!
$SOLY moon shot !
$SOLY let’s go!!!!! $12+ today!!!
Let’s go $SOLY!!!!
HOUSTON, Nov. 21, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it has entered into a Cooperative Development Agreement with Emphysys, an interdisciplinary technology and product development firm just outside Boston, for design and engineering services related to the Company's acoustical shockwave technology.
Under the terms of the agreement, Emphysys will provide engineering and design services related to shockwave technology for use in dermatology and aesthetics fields to Soliton for a three-year period.
Join our more than 200K fans here to follow the Company: https://soly-investors.com
Dr. Chris Capelli, Soliton President, CEO and co-founder comments, "This partnership with Emphysys protects Soliton's development efforts as we move through the coming stages of commercialization. Emphysys was instrumental to the early development of our technology and their continued involvement helps to ensure that we launch a robust, capable device. Our latest device iteration is designed with both the removal of tattoos and the reduction of cellulite in mind and we are excited to begin efforts towards a commercially viable platform device with Emphysys' support."
Emphysys, Inc. is a technology and product development partner to leading companies and emerging startups in the Medical Device, Life Science, and Industrial markets. With unmatched expertise in fundamental science, multi-modal energy generation, software control systems, and sophisticated simulation and modeling capabilities, the company's interdisciplinary teams of world-class engineers and scientists focus on developing highly complex technology and energy-based products on unprecedented time scales.
Ali Shajii, President and CEO of Emphysys, said, "We value our long-term partnership with Soliton and are excited to continue our collaboration on this pioneering new technology. Our shared mindset of developing and delivering truly differentiable products makes this a remarkable partnership."
For more information about Emphysys, please visit: www.emphysys.com
PR tomorrow and we are back to at least $13+++!! $SOLY
$SOLY IE( Sales Plan, Marketing Plan, licensing deal?, Sales forecast for 2020)
Rich: $SOLY They are doing follow up appointments now for cellulite.
Cellulite indication for FDA APPROVAL will not be given until the first or 2nd Qtr of 2020. However, we will have RAP for tattoos rolling out Qtr 1 of 2020. This will help stabilize stock price around $20-$30 in my opinion.
$SOLY HUGE NEWS TOMORROW AM!!!